Gt biopharma affirms manufacturing timeline for lead investigational asset gtb-3650

Brisbane, calif., aug. 30, 2022 (globe newswire) -- gt biopharma, inc. (the “company” or “gtb”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced entering into a settlement and investment agreement (the “agreement”) with its contract manufacturing partner cytovance biologics. the signed agreement, covers all work required to facilitate the registration of an investigational new drug (ind) filing with the u.s. food and drug administration (“fda”) of its lead investigational asset gtb-3650.
GTBP Ratings Summary
GTBP Quant Ranking